Can WeightWatchers survive the Wegovy era?

The 1873 Gründerkrach, the spectacular stock market crash that followed Germany’s unification, is one of history’s great financial maelstroms. But its most enduring legacy isn’t about money. Host Robin Wigglesworth speaks to Pulitzer Prize-winning author Liaquat Ahamed about how ...  Show more

Ancient Rome is often depicted as a glamorous empire of power, sophistication and wealth. Yet for most people, the reality of daily life was precarious. Host Robin Wigglesworth talks to Kim Bowes, author of Surviving Rome: The Economic Lives of the Ninety Percent, about how ordin ...  Show more

Long before WeightWatchers became a weight loss empire, the legacy dieting company started as a small support group in the 1960s. The company rose to popularity preaching a message of moderation and making healthy choices. But in what some call a surprising pivot, WeightWatchers ...  Show more

WeightWatchers is going all-in on trendy new anti-obesity drugs. The gamble might save the company—if it doesn’t kill it first. By Emma Court and Ellen HuetSee omnystudio.com/listener for privacy information. 

First there was Weight Watchers, then there was Noom, and now there’s…Wegovy? Bloomberg health reporter Emma Court helps us understand the evolution of dieting programs and where they’re going next. Later, Matthew Schnier of New York Magazine and The Cut walks us through his arti ...  Show more

Weight-loss drugs have become a golden formula for pharma growth. In this episode we speak to Sector Advisor Maria Latorre and Senior Economist Michaela Grimm about how GLP-1 treatments like Ozempic and Wegovy are reshaping the industry, and the risks that lie ahead. SHOWNOTES: • ...  Show more